Physician profile
Tyler Cooper
NPI 1649775024
$5,421.88
in general payments reported to CMS, 2019-2025
13 companies · $960 in 2025
The $960 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $33.12 · 2023: $204 · 2024: $4,225 · 2025: $960.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $2,500 · Food and Beverage: $1,455 · Travel and Lodging: $1,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $2,500.00 |
| Food and Beverage | $1,455.19 |
| Travel and Lodging | $1,433.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $3,968.55 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $406.35 | 2022-2025 | Tezspire, Fasenra, Breztri |
| Abiomed | $256.69 | 2024-2025 | Impella |
| Verona Pharma, INC. | $233.31 | 2025 | Ohtuvayre |
| Ucb, INC. | $114.32 | 2024 | Briviact |
| Paratek Pharmaceuticals, INC. | $112.73 | 2025 | Nuzyra |
| Insmed, INC. | $107.56 | 2025 | Arikayce |
| Erbe USA INC | $88.00 | 2025 | Vio3apc3cryo2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.82 | 2023-2025 | Ofev |
| Janssen Pharmaceuticals, INC | $19.95 | 2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $17.11 | 2024 | Glassia |
| Merck Sharp & Dohme LLC | $15.41 | 2023 | Recarbrio, Zerbaxa, Dificid |
| Glaxosmithkline, LLC. | $15.08 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tyler Cooper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.